S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
OTCMKTS:AOLS

Aeolus Pharmaceuticals (AOLS) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
15,776 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.


AOLS Stock News Headlines

Aeolus Pharmaceuticals Inc
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Aeolus Pharmaceuticals, Inc. (AOLS)
Aeolus Pharmaceuticals Inc.
See More Headlines
Receive AOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeolus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AOLS Company Calendar

Last Earnings
8/14/2017
Today
10/02/2023
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:AOLS
Employees
4
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.55
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. John L. Mcmanus (Age 59)
    Chief Exec. Officer and Pres
    Comp: $460.33k
  • Mr. Christopher Stanley
    VP of Operations













AOLS Stock - Frequently Asked Questions

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) issued its earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter.

What other stocks do shareholders of Aeolus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeolus Pharmaceuticals investors own include iBio (IBIO), Myriad Genetics (MYGN), Synergy Pharmaceuticals (SGYP), Titan Pharmaceuticals (TTNP), ADOMANI (ADOM), Agritek (AGTK), Akers Biosciences (AKER), Argos Therapeutics (ARGSQ), Arena Pharmaceuticals (ARNA) and Biohaven (BHVN).

What is Aeolus Pharmaceuticals' stock symbol?

Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."

How do I buy shares of Aeolus Pharmaceuticals?

Shares of AOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How can I contact Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The official website for the company is www.aeoluspharma.com. The biopharmaceutical company can be reached via phone at (949) 481-9825, via email at info@amstock.com, or via fax at 949-481-9829.

This page (OTCMKTS:AOLS) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -